Amgen and Novartis are working together to fight against migraines with erenumab, an expanded commercial collaboration building on a global neuroscience collaboration in Alzheimer's disease and migraine established in 2015.
“This expanded collaboration leverages Novartis' strong and established presence in neuroscience to more effectively reach people with migraine," a press release said.
Together, both companies will combine forces to co-commercialzie erenumab in the U.S. Amgen has erenumab rights in Japan, while Novartis has the same in Canada.
Specifically, erenumab is an antibody designed to “target and block the Calcitonin Gene-Related Peptide (CGRP) receptor, believed to have a critical role in mediating the incapacitating pain of migraine.”
Phase 2 study data revealed it could help with migraines, and a detailed report of data will be presented at the annual meeting of the American Academy of Neurology.
“These data will help support discussions with regulatory agencies, with filing anticipated in the second quarter of 2017,” the release read.
Amgen will receive payments from Novartis beginning this year, as the companies share costs.
“Amgen will book sales of erenumab in the U.S., and will pay a royalty to Novartis on net sales in the U.S. Novartis will book sales in the rest of the world, excluding Japan, and will pay Amgen royalties on the net sales in those countries.”
Alerts Sign-up